# US 7,745,404 B2 · Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,404 B2
- Document ID: US7745404B2
- Status: Granted
- Kind: B2
- Application number: 11/952,729
- Filed: 2007-12-07
- Published: 2008-06-19
- Granted: 2010-06-29
- Earliest claimed: 2002-09-05
- Assignees: Wisconsin Alumni Research Foundation
- Inventors: Hector F. DeLuca; Terrence F. Meehan; Bryan R. Becklund; Margaret Clagett-Dame
- Web page: https://patentgrep.com/patent/US7745404B2

## CPC

- A61K 38/225: {Calcitonin gene related peptide}
- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K 38/23: Calcitonins
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating and preventing multiple sclerosis by administering to a patient an effective amount of calcitonin, calcitonin-like peptides or calcitonin mimetics to a patient. Additionally, 1,25-dihydroxyvitamin D analogs can be used in combination with the calcitonin, calcitonin-like peptides or calcitonin mimetics.

## Claims

### Claim 1

A method for treating multiple sclerosis symptoms comprising the steps of
(a) selecting a multiple sclerosis patient in need thereof, and
(b) administering an amount of salmon calcitonin to the patient, wherein the amount is sufficient to treat said multiple sclerosis symptoms.

### Claim 2 (depends on 1)

The method of claim 1 wherein the patient is female.

### Claim 3 (depends on 1)

The method of claim 1 additionally comprising the step of administering an amount of 1,25-dihydroxyvitamin D analog effective to reduce multiple sclerosis symptoms.

### Claim 4 (depends on 1)

The method of claim 1 wherein the amount of salmon calcitonin is between 100-1000 μg/day.

### Claim 5 (depends on 4)

The method of claim 4 wherein the patient is treated with an injection of 500 μg (±10) of salmon calcitonin.

### Claim 6 (depends on 1)

The method of claim 1 wherein the salmon calcitonin is in dosage form and the dose of salmon calcitonin is 5-200 IU per day.

### Claim 7 (depends on 1)

The method of claim 1 wherein the salmon calcitonin is in dosage form and the dose is administered via colonic administration and the dose is 40-800 IU per day.

### Claim 8 (depends on 1)

The method of claim 1 wherein the diminished symptoms are selected from the group consisting of tingling, numbness, loss of balance, weakness, double vision, fatigue, incontinence, paralysis, memory and speech difficulties.

### Claim 9 (depends on 3)

The method of claim 3 wherein the vitamin D analog is selected from the group of 1α,25-dihydroxyvitamin D3 (1,25-(OH)2D3), 19-nor-1,25-dihydroxyvitamin D2 (19-nor-1,25-(OH)2D3), 24-homo-22-dehydro-22E-1α,25-dihydroxyvitamin D3 (24-homo-22-dehydro-22E-1,25-(OH)2D3), 1,25-dihydroxy-24(E)-dehydro-24-homo-vitamin D3 (1,25-(OH)2-24-homo D3), and 19-nor-1,25-dihydroxy-21-epi-vitamin D3 (19-nor-1,25-(OH)2-21-epi-D3).

### Claim 10 (depends on 1)

The method of claim 1 wherein the salmon calcitonin is administered intravenously.

### Claim 11 (depends on 1)

The method of claim 1 wherein the salmon calcitonin is administered by a route selected from the group consisting of oral, intravenous, colonic, nasal, and aerosol administration.